10.2.3. Other neuromuscular drugs
Restrictions:
Restricted to specialist use only for the treatment of type II and III 5q spinal muscular atrophy (SMA).
Prescribing Notes:
- This therapy is available via the Scottish Government Ultra-orphan pathway
- Formulary status will be reconsidered following the reassessment by SMC (expected July 2022).
- SMA type I is already accepted for use by SMC and is available in the GGC Paediatric Formulary.
Restrictions:
Restricted to specialist use for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders.
Prescribing Notes:
For other indications please see section 2.3.2
Restrictions:
Restricted to specialist use only in the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA type 1, type 2 or type 3 or with one to four SMN2 [survival of motor neuron 2] copies.
Restrictions:
Restricted to specialist use only.
Prescribing Notes:
Ataluren may be prescribed within the ultra-orphan pathway while further evidence on its effectiveness is generated. In 2025, the SMC will evaluate the medicine for routine use in NHS Scotland. This medicine is part of the national Ultra-Orphan Risk Share Scheme.